Rhythm Pharmaceuticals
RYTM
168 hedge funds and large institutions have $3.08B invested in Rhythm Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 42 increasing their positions, 63 reducing their positions, and 19 closing their positions.
1,509% more call options, than puts
Call options by funds: $50M | Put options by funds: $3.11M
132% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 19
97% more capital invested
Capital invested by funds: $1.56B → $3.08B (+$1.51B)
43% more funds holding in top 10
Funds holding in top 10: 7 → 10 (+3)
17% more funds holding
Funds holding: 143 → 168 (+25)
6.5% less ownership
Funds ownership: 119.74% → 113.24% (-6.5%)
33% less repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 63
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$55.9M |
| 2 |
Pictet Asset Management
Carouge,
Switzerland
|
+$36.7M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$11.4M |
| 4 |
Voloridge Investment Management
Jupiter,
Florida
|
+$10.8M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$10.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alkeon Capital Management
New York
|
-$39.5M |
| 2 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$23.7M |
| 3 |
VA
VR Adviser
New York
|
-$18.7M |
| 4 |
CC
Commodore Capital
New York
|
-$16.6M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
-$14M |
RYTM Hedge Fund Activity: Q4 2023 in Review
168 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Rhythm Pharmaceuticals (RYTM) for Q4 2023, worth a combined $3.08B — up 97% from $1.56B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new RYTM positions and 19 closed out — a net gain of 25 holders — while 42 added to existing stakes and 63 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $55.9M. The largest seller was Alkeon Capital Management, exiting entirely with an estimated $39.5M sold.
- 168 institutional investors held Rhythm Pharmaceuticals (RYTM) as of Q4 2023, up from 143 in Q3 2023.
- Funds reported $3.08B of Rhythm Pharmaceuticals stock for Q4 2023, up 97% quarter-over-quarter.
- 44 funds opened new Rhythm Pharmaceuticals positions in Q4 2023 and 19 closed out, a net change of +25 holders.
- The largest Rhythm Pharmaceuticals buyer in Q4 2023 was Perceptive Advisors, an estimated $55.9M added.
- The largest Rhythm Pharmaceuticals seller in Q4 2023 was Alkeon Capital Management, an estimated $39.5M sold.
Based on aggregated 13F filings for Q4 2023.